StreetInsider.com News Articles

Form 6-K Scinai Immunotherapeutic For: Oct 16

Fri, 16 Oct 2026 10:05:00 -0400

si-local-file:///var/storage/secattach/20261016/27196576.html

Scinai closes $4M private placement and warrant inducement

Fri, 16 Oct 2026 08:00:14 -0400

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has closed a private placement and warrant inducement transaction, raising approximately $4.0 million in gross proceeds before placement agent fees and expenses.

The private placement involved 2,458,334 American Depositary Shares, or pre-funded warrants in lieu thereof, each representing 40,000 ordinary shares, along with Series A-1 Warrants to purchase up to 3,687,501 ADSs. The company also closed an immediate exercise of existing warrants to purchase up to 879,194 ADSs at a reduced exercise price of $1.20 per ADS, with additional Series A-1 Warrants issued to purchase up to 1,318,791 ADSs.

A.G.P./Alliance Global Partners served as the sole placement

Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement

Fri, 16 Oct 2026 08:00:00 -0400

JERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced the closing of its previously announced private placement of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, together with Series A-1 Warrants to

Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement

Fri, 16 Oct 2026 08:00:00 -0400

Form 6-K Scinai Immunotherapeutic For: Oct 15

Thu, 15 Oct 2026 09:41:00 -0400

si-local-file:///var/storage/secattach/20261015/27191182.html

Scinai Immunotherapeutics raises $4M via private placement and warrants

Wed, 14 Oct 2026 08:01:27 -0400

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced it has entered into a securities purchase agreement with an existing life sciences institutional investor, expecting to raise approximately $4.0 million in gross proceeds through a private placement and warrant inducement transaction.

Under the private placement, the Jerusalem-based biopharmaceutical company will issue 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in lieu thereof, each ADS representing 40,000 ordinary shares. The combined purchase price is $1.20 per ADS and accompanying Series A-1 warrants, which carry an exercise price of $1.20 per ADS, are exercisable immediately, and have a five-year term.

Separately, the company entered into a warrant

Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement

Wed, 14 Oct 2026 08:00:00 -0400

JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced that it has entered into a securities purchase agreement with an existing life sciences institutional investor for the purchase and sale of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing

Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement

Wed, 14 Oct 2026 08:00:00 -0400

Form 6-K Scinai Immunotherapeutic For: Oct 13

Tue, 13 Oct 2026 07:51:00 -0400

si-local-file:///var/storage/secattach/20261013/27177203.html

Scinai signs $5.1M CDMO deal with Nasdaq-listed biopharma

Tue, 13 Oct 2026 07:01:51 -0400

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a development and clinical manufacturing agreement worth approximately $5.1 million in committed base service fees with an undisclosed U.S.-based, Nasdaq-listed biopharmaceutical company.

The agreement covers integrated chemistry, manufacturing and controls development and clinical manufacturing for an investigational oncology product. Services include process and analytical development, manufacturing readiness, IND-enabling activities, a clinical manufacturing program, stability testing and development of a prefilled-syringe presentation. Revenue from the agreement is expected to be recognized during 2026 and 2027, with stability services continuing beyond 2027.

Following the agreement, Scinai's

Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Tue, 13 Oct 2026 07:00:00 -0400

Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025

Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in 2026 and clinical manufacturing planned for 2027

Potential additional clinical manufacturing carries an indicative, uncommitted service-fee value of $5.85 million for late

Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Tue, 13 Oct 2026 07:00:00 -0400

Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025

Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in 2026 and clinical manufacturing planned for 2027

Potential additional clinical manufacturing carries an indicative, uncommitted service-fee value of $5.85 million for late

Form EFFECT Scinai Immunotherapeutic

Tue, 06 Oct 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20261006/27151353.html

Form F-1 Scinai Immunotherapeutic

Thu, 24 Sep 2026 16:22:00 -0400
si-local-file:///var/storage/secattach/20260924/27102464.html

Scinai regains Nasdaq minimum bid price compliance

Mon, 21 Sep 2026 07:01:10 -0400

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced it received written notification from Nasdaq Listing Qualifications confirming the company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Nasdaq notified Scinai on March 12, 2026, that the company's American Depositary Shares had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days.

In a compliance letter dated September 18, 2026, Nasdaq stated that for 19 consecutive business days from August 21, 2026, through September 17, 2026, the closing bid price of Scinai's ADSs was at $1.00 per share or greater, satisfying the

Form 6-K Scinai Immunotherapeutic For: Sep 21

Mon, 21 Sep 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260921/27082825.html

Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mon, 21 Sep 2026 07:00:00 -0400

Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed

JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract

Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mon, 21 Sep 2026 07:00:00 -0400

Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed

JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract

Form POS AM Scinai Immunotherapeutic

Thu, 27 Aug 2026 11:36:00 -0400
si-local-file:///var/storage/secattach/20260827/26987568.html

Form POS AM Scinai Immunotherapeutic

Thu, 27 Aug 2026 11:36:00 -0400
si-local-file:///var/storage/secattach/20260827/26987568.html

Form 6-K Scinai Immunotherapeutic For: Jun 30

Wed, 26 Aug 2026 08:14:00 -0400
si-local-file:///var/storage/secattach/20260826/26977624.html

Form 6-K Scinai Immunotherapeutic For: Jun 30

Wed, 26 Aug 2026 08:14:00 -0400
si-local-file:///var/storage/secattach/20260826/26977624.html

Scinai posts H1 2026 results with wider operating loss, net gain

Mon, 24 Aug 2026 07:06:53 -0400

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported financial results for the six months ended June 30, 2026, showing revenue growth alongside a wider operating loss, according to a press release from the Jerusalem-based biopharmaceutical and contract development and manufacturing organization (CDMO) company.
Revenue rose to $949 thousand from $773 thousand in the same period of 2025, attributed primarily to the inclusion of revenues from the acquired Yavne operations. Cost of revenues increased to $3.3 million from $2.0 million, reflecting expanded costs following the acquisition. The gross loss widened to approximately $2.4 million from $1.3 million in the prior-year period.
The operating loss was

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Mon, 24 Aug 2026 07:00:00 -0400

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT
JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today provided a corporate update and reported financial results for the six months ended June 30, 2026.

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT
JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today provided a corporate update and reported financial results for the six months ended June 30, 2026.